119 related articles for article (PubMed ID: 1409189)
1. Treatment of Raynaud's phenomenon with triiodothyronine corrects co-existent autonomic dysfunction: preliminary findings.
Gledhill RF; Dessein PH; Van der Merwe CA
Postgrad Med J; 1992 Apr; 68(798):263-7. PubMed ID: 1409189
[TBL] [Abstract][Full Text] [Related]
2. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
Kahan A; Amor B; Menkes CJ
Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
[TBL] [Abstract][Full Text] [Related]
3. Autonomic neuropathy in systemic sclerosis.
Klimiuk PS; Taylor L; Baker RD; Jayson MI
Ann Rheum Dis; 1988 Jul; 47(7):542-5. PubMed ID: 3401050
[TBL] [Abstract][Full Text] [Related]
4. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
[TBL] [Abstract][Full Text] [Related]
5. Autonomic neuropathy in systemic lupus erythematosus: cardiovascular autonomic function assessment.
Lioté F; Osterland CK
Ann Rheum Dis; 1994 Oct; 53(10):671-4. PubMed ID: 7979580
[TBL] [Abstract][Full Text] [Related]
6. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon.
Pancera P; Sansone S; Presciuttini B; Montagna L; Cerù S; Lunardi C; Lechi A
Clin Sci (Lond); 1999 Jan; 96(1):49-57. PubMed ID: 9857106
[TBL] [Abstract][Full Text] [Related]
7. Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus.
Aydemir M; Yazisiz V; Basarici I; Avci AB; Erbasan F; Belgi A; Terzioglu E
Lupus; 2010 Mar; 19(3):255-61. PubMed ID: 20015916
[TBL] [Abstract][Full Text] [Related]
8. Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk.
Milovanović B; Stojanović L; Milićevik N; Vasić K; Bjelaković B; Krotin M
Srp Arh Celok Lek; 2010; 138(1-2):26-32. PubMed ID: 20422909
[TBL] [Abstract][Full Text] [Related]
9. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
10. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
11. Autonomic dysfunction in primary Raynaud's phenomenon.
Koszewicz M; Gosk-Bierska I; Bilińska M; Podemski R; Budrewicz S; Adamiec R; Słotwiński K
Int Angiol; 2009 Apr; 28(2):127-31. PubMed ID: 19367242
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases.
Stojanovich L; Milovanovich B; de Luka SR; Popovich-Kuzmanovich D; Bisenich V; Djukanovich B; Randjelovich T; Krotin M
Lupus; 2007; 16(3):181-5. PubMed ID: 17432103
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
14. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial.
Dessein PH; Morrison RC; Lamparelli RD; van der Merwe CA
J Rheumatol; 1990 Aug; 17(8):1025-8. PubMed ID: 2213778
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
16. The mechanisms of Raynaud's phenomenon: Part 2.
McGrath MA; Penny R
Med J Aust; 1974 Sep; 2(10):367-75. PubMed ID: 4608542
[No Abstract] [Full Text] [Related]
17. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
[TBL] [Abstract][Full Text] [Related]
18. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
19. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
[TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon and systemic sclerosis.
Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
